#PARP inhibitors

Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.

Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.

Gaby Kressly, now in her early 80s, was diagnosed with ovarian cancer in 2016.

Lynparza (olaparib) may become standard follow-up therapy for women with newly diagnosed ovarian cancer that has a BRCA mutation.

A look back at some of the major news stories we covered this year.

PARP inhibitor slowed disease progression in clinical study.

Talazoparib slowed disease progression compared to chemotherapy in EMBRACA study.

The PARP inhibitor Lynparza slows disease progression in women with BRCA-related ovarian cancer.

The drug, a PARP inhibitor, blocks proteins that help repair damaged DNA, and so can cause tumor cells that carry a BRCA mutation to die.

In tumors with missing or mutated BRCA genes, PARP inhibitors plus other drugs have worked well—but the cancer often becomes drug-resistant.

Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.

PARP inhibitor demonstrates unprecedented improvement in progression-free survival.

Small Phase I trial saw an increased survival rate in people with locally advanced head and neck cancer and a history of heavy smoking.